On November 19, 2020, a unanimous panel of the Court of Appeals for the Federal Circuit (“Federal Circuit”) decided Vectura Ltd. v. GlaxoSmithKline LLC, affirming a $90 million verdict. Vectura Ltd. (“Vectura”) sued...more
12/1/2020
/ Claim Construction ,
Damages ,
Judgment As A Matter Of Law ,
Patent Applications ,
Patent Infringement ,
Patent Royalties ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Post Trial Motions ,
Remittitur
Recently, the Federal Circuit issued a decision in Immunex Corp. v. Sanofi-Aventis U.S. LLC addressing the different claim construction standards used by the Patent Trial and Appeal Board (“PTAB”) (broadest reasonable...more
11/25/2020
/ Broadest Reasonable Interpretation Standard ,
Claim Construction ,
Corporate Counsel ,
Ex Partes Reexamination ,
Inter Partes Review (IPR) Proceeding ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Phillips Standard ,
Prior Art ,
Reissue Patents ,
USPTO